All In Biotech

Drug Trial Radar · NCT02978183

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model

Last checked: Nov 19, 2026Latest source record: Apr 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Dec 2016

Primary completion

Feb 2017

Study completion Nov 2017

Sponsor

Sponsor type
Industry
First posted
Nov 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

  • ST266Biological

    One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.

  • Saline (0.9% NaCl)Drug

    One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular ItchingTime frame: Day 7 and 8
  2. Conjunctival RednessTime frame: Day 7 and 8

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Andover, Massachusetts

  • Site not named

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.